SCHOTT Pharma KGaA (1SXP) Aandelenoverzicht
SCHOTT Pharma AG & Co. KGaA ontwikkelt, produceert en verkoopt wereldwijd oplossingen voor het insluiten van medicijnen en afgiftesystemen voor injecteerbare medicijnen voor de farmaceutische, biotechnologische en biowetenschappelijke industrie. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 1/6 |
| Prestaties in het verleden | 2/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 2/6 |
Beloningen
Risicoanalyse
Geen risico's gedetecteerd voor 1SXP uit onze risicocontroles.
1SXP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
SCHOTT Pharma AG & Co. KGaA Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | €16.98 |
| 52 Week Hoogtepunt | €30.25 |
| 52 Week Laag | €12.62 |
| Bèta | 0.89 |
| 1 maand verandering | 10.98% |
| 3 maanden verandering | 11.27% |
| 1 Jaar Verandering | -39.47% |
| 3 jaar verandering | n/a |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | -45.75% |
Recent nieuws en updates
Analyseartikel • May 16
SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Investors in SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) had a good week, as its shares rose 4.9% to close at €16.38...
Narratiefupdate • May 15
1SXP: Lower Discount Rate And Solid Margins Will Support Undervalued Shares
Analysts have kept their €25.90 price target for SCHOTT Pharma KGaA unchanged, citing a slightly lower discount rate, modestly higher revenue growth and profit margin assumptions, and a marginally lower future P/E multiple in their updated models. Valuation Changes Fair Value: The €25.90 price estimate is unchanged, indicating no revision to the overall valuation outcome.
Narratiefupdate • Apr 29
1SXP: 2026 Guidance And Dividend Policy Will Support Future Upside
The analyst price target for SCHOTT Pharma KGaA has been adjusted slightly to €19.14 from €19.23, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that analysts see as largely offsetting one another. What's in the News SCHOTT Pharma AG & Co. KGaA confirmed earnings guidance for the 2026 financial year, maintaining its forecast for revenue growth at constant currencies of 2 to 5% (company guidance).Recent updates
Analyseartikel • May 16
SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Investors in SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) had a good week, as its shares rose 4.9% to close at €16.38...Narratiefupdate • May 15
1SXP: Lower Discount Rate And Solid Margins Will Support Undervalued Shares
Analysts have kept their €25.90 price target for SCHOTT Pharma KGaA unchanged, citing a slightly lower discount rate, modestly higher revenue growth and profit margin assumptions, and a marginally lower future P/E multiple in their updated models. Valuation Changes Fair Value: The €25.90 price estimate is unchanged, indicating no revision to the overall valuation outcome.Narratiefupdate • Apr 29
1SXP: 2026 Guidance And Dividend Policy Will Support Future Upside
The analyst price target for SCHOTT Pharma KGaA has been adjusted slightly to €19.14 from €19.23, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that analysts see as largely offsetting one another. What's in the News SCHOTT Pharma AG & Co. KGaA confirmed earnings guidance for the 2026 financial year, maintaining its forecast for revenue growth at constant currencies of 2 to 5% (company guidance).Narratiefupdate • Apr 14
1SXP: Dividend Policy And 2026 Guidance Will Support Future Profitability
Analysts have adjusted their price target for SCHOTT Pharma KGaA to €19.23 from €22.97, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News SCHOTT Pharma AG & Co. KGaA confirmed earnings guidance for the 2026 financial year, with the company expecting revenue growth at constant currencies of 2 to 5% (Corporate guidance).Narratiefupdate • Mar 31
1SXP: Dividend And 2026 Earnings Guidance Will Support Confidence In Undervalued Shares
Analysts have kept their price target for SCHOTT Pharma KGaA steady at €25.90, indicating relatively unchanged assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E in their updated models. What's in the News SCHOTT Pharma AG & Co. KGaA confirmed its earnings guidance for the 2026 financial year, expecting revenue growth at constant currencies of 2 to 5% (company guidance).Narratiefupdate • Mar 17
1SXP: Dividend And 2026 Guidance Will Support Confidence In Undervalued Shares
Analysts have maintained the price target for SCHOTT Pharma KGaA at €25.90. They cited only minor adjustments to inputs such as the discount rate, revenue growth assumptions, profit margin, and future P/E, which did not materially affect their overall valuation view.Narratiefupdate • Mar 03
1SXP: Dividend And Mid Term Outlook Will Support Confidence In Undervalued Shares
Analysts have maintained their €25.90 price target for SCHOTT Pharma KGaA, citing only modest adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E that they view as too small to change their overall assessment. What's in the News SCHOTT Pharma confirmed earnings guidance for the 2026 financial year, reiterating its forecast for revenue growth at constant currencies of 2 to 5% (company guidance).Narratiefupdate • Feb 17
1SXP: Dividend Initiation Will Support Confidence In Updated Mid Term Outlook
Analysts have nudged their price target for SCHOTT Pharma KGaA slightly lower from €26.00 to €25.90, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E multiples. What's in the News The Annual General Meeting on February 3, 2026 approved a dividend of €0.18 per share, with a payout ratio of 18% of consolidated net income (company announcement).Analyseartikel • Feb 14
SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) defied analyst predictions to release its first-quarter results, which were...
Narratiefupdate • Feb 02
1SXP: Fair Outlook Will Balance Dividend Payout With Leadership Transition
Analysts have kept their price target for SCHOTT Pharma KGaA steady at €14.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin and future P/E that they see as balancing out overall. What's in the News SCHOTT Pharma AG & Co. KGaA announced an annual dividend of €0.18 per share, payable on February 6, 2026, with an ex date of February 4, 2026, and a record date of February 5, 2026 (Key Developments).Analyseartikel • Feb 02
There Is A Reason SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) Price Is Undemanding
When close to half the companies in Germany have price-to-earnings ratios (or "P/E's") above 18x, you may consider...Narratiefupdate • Jan 19
1SXP: Dividend Initiation Will Support Confidence In Revised Long Term Outlook
Analysts have reduced their price target for SCHOTT Pharma KGaA from €36.00 to €26.00, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E, which point to a more conservative outlook on the shares' fair value. What's in the News SCHOTT Pharma AG & Co. KGaA announced an annual dividend of €0.18 per share, with payment scheduled for February 6, 2026, an ex dividend date on February 4, 2026, and a record date on February 5, 2026 (Key Developments).Narratiefupdate • Jan 05
1SXP: Leadership Transition And Dividend Policy Will Support Future Profitability
Analysts have trimmed their fair value estimate for SCHOTT Pharma KGaA from €28.28 to €22.97, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple as key drivers of the change. What's in the News SCHOTT Pharma AG & Co. KGaA announced an annual dividend of €0.18 per share, with payment scheduled for February 6, 2026, ex-date on February 4, 2026, and record date on February 5, 2026 (Key Developments).Narratiefupdate • Dec 20
1SXP Outlook Will Balance Lower Expectations With Dividend And Leadership Transition
Analysts have reduced their price target on SCHOTT Pharma KGaA from €22.00 to €14.00, reflecting tempered expectations for revenue growth, profit margins, and future valuation multiples in an environment characterized by higher discount rates. What's in the News SCHOTT Pharma AG & Co. KGaA declared an annual dividend of EUR 0.18 per share, payable on February 6, 2026, with an ex-dividend date of February 4, 2026, and a record date of February 5, 2026 (Key Developments).Analyseartikel • Dec 15
SCHOTT Pharma KGaA (ETR:1SXP) Will Pay A Larger Dividend Than Last Year At €0.18
SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) has announced that it will be increasing its periodic dividend on the 6th of...Narratiefupdate • Dec 06
1SXP: Leadership Transition Will Support Future Profitability And Operational Discipline
Analysts have modestly reduced their price target for SCHOTT Pharma KGaA by approximately €0.90. This reflects slightly lower assumptions for revenue growth, profit margins, and future valuation multiples, alongside a marginally higher discount rate.Analyseartikel • Nov 24
A Look At The Fair Value Of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
Key Insights SCHOTT Pharma KGaA's estimated fair value is €21.30 based on 2 Stage Free Cash Flow to Equity With €18.44...Narratiefupdate • Nov 22
1SXP: Leadership Transition Will Drive Renewed Operational Focus And Profitability
Analysts have modestly lowered their price target for SCHOTT Pharma KGaA from €29.33 to €29.19, citing slight reductions in anticipated revenue growth and profit margins, as well as a higher discount rate used in their updated valuation models. What's in the News Christian Mias appointed as CEO of SCHOTT Pharma KGaA.Analyseartikel • Nov 02
Is SCHOTT Pharma KGaA (ETR:1SXP) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analyseartikel • Sep 19
Investor Optimism Abounds SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) But Growth Is Lacking
When close to half the companies in Germany have price-to-earnings ratios (or "P/E's") below 18x, you may consider...Analyseartikel • Aug 15
Analysts Are Updating Their SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Estimates After Its Third-Quarter Results
Last week, you might have seen that SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) released its quarterly result to the...Analyseartikel • Jul 19
These 4 Measures Indicate That SCHOTT Pharma KGaA (ETR:1SXP) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analyseartikel • Jun 13
Does SCHOTT Pharma KGaA (ETR:1SXP) Deserve A Spot On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analyseartikel • May 18
Earnings Beat: SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) came out with its second-quarter results last week, and we wanted to see how...Analyseartikel • Apr 27
An Intrinsic Calculation For SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Suggests It's 40% Undervalued
Key Insights SCHOTT Pharma KGaA's estimated fair value is €39.60 based on 2 Stage Free Cash Flow to Equity SCHOTT...Analyseartikel • Mar 22
We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Feb 12
SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Investors Are Less Pessimistic Than Expected
When close to half the companies in Germany have price-to-earnings ratios (or "P/E's") below 16x, you may consider...Analyseartikel • Jan 13
Is SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Trading At A 49% Discount?
Key Insights SCHOTT Pharma KGaA's estimated fair value is €49.59 based on 2 Stage Free Cash Flow to Equity SCHOTT...
Nieuw narratief • Dec 16
Global Expansion And Innovative Pharma Solutions Set To Boost Revenue And Profitability
SCHOTT Pharma's global expansion and innovative product offerings are expected to drive revenue growth and improve profitability by meeting market demand and increasing efficiencies.Analyseartikel • Nov 25
These 4 Measures Indicate That SCHOTT Pharma KGaA (ETR:1SXP) Is Using Debt Reasonably Well
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Oct 27
SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) Business Is Trailing The Market But Its Shares Aren't
SCHOTT Pharma AG & Co. KGaA's ( ETR:1SXP ) price-to-earnings (or "P/E") ratio of 31.5x might make it look like a strong...Analyseartikel • Sep 01
SCHOTT Pharma AG & Co. KGaA Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) investors will be delighted, with the company turning in some strong numbers...Analyseartikel • Aug 07
Is There An Opportunity With SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) 31% Undervaluation?
Key Insights SCHOTT Pharma KGaA's estimated fair value is €47.81 based on 2 Stage Free Cash Flow to Equity Current...Analyseartikel • Jul 01
Earnings Miss: SCHOTT Pharma AG & Co. KGaA Missed EPS By 18% And Analysts Are Revising Their Forecasts
It's been a pretty great week for SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) shareholders, with its shares surging 11% to...Analyseartikel • Jun 07
We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Mar 28
Calculating The Intrinsic Value Of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
Key Insights The projected fair value for SCHOTT Pharma KGaA is €34.80 based on 2 Stage Free Cash Flow to Equity SCHOTT...Rendement voor aandeelhouders
| 1SXP | DE Life Sciences | DE Markt | |
|---|---|---|---|
| 7D | 3.7% | 11.9% | 3.2% |
| 1Y | -39.5% | -10.8% | 2.5% |
Rendement versus industrie: 1SXP presteerde slechter dan de German Life Sciences -sector, die het afgelopen jaar een rendement van -10.8 % opleverde.
Rendement versus markt: 1SXP presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 2.5 % opleverde.
Prijsvolatiliteit
| 1SXP volatility | |
|---|---|
| 1SXP Average Weekly Movement | 3.9% |
| Life Sciences Industry Average Movement | 9.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.6% |
| 10% least volatile stocks in DE Market | 2.7% |
Stabiele aandelenkoers: 1SXP heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de German markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van 1SXP is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1884 | 4,839 | Christian Mias | www.schott-pharma.com |
SCHOTT Pharma AG & Co. KGaA ontwikkelt, produceert en verkoopt wereldwijd oplossingen voor het insluiten van medicijnen en afgiftesystemen voor injecteerbare medicijnen voor de farmaceutische, biotechnologische en biowetenschappelijke industrie. Het bedrijf biedt voorvulbare glazen of polymeer spuiten, glazen flacons, cartridges en ampullen. De spuitproducten omvatten syriQ, een glazen spuit voor vaccins; syriQ BioPure, een glazen spuit voor biologische geneesmiddelen; syriQ BioPure siliconenvrij, een voorvulbare en siliconenvrije glazen spuit voor biologische geneesmiddelen; SCHOTT TOPPAC, een polymeer spuit; SCHOTT TOPPAC cosmetic, een polymeer spuit voor esthetische behandelingen; SCHOTT TOPPAC freeze, een polymeerspuit voor diepkoude toepassingen; SCHOTT TOPPAC sensitive, een polymeerspuit voor gevoelige geneesmiddelen; SCHOTT TOPPAC infuse, een polymeerspuit voor infuustherapie; en SCHOTT TOPPAC unique, een polymeercontainer.
SCHOTT Pharma AG & Co. KGaA Samenvatting
| 1SXP fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | €2.56b |
| Inkomsten(TTM) | €142.82m |
| Inkomsten(TTM) | €991.22m |
17.9x
Koers/Winstverhouding2.6x
P/S-verhoudingIs 1SXP overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| 1SXP resultatenrekening (TTM) | |
|---|---|
| Inkomsten | €991.22m |
| Kosten van inkomsten | €664.75m |
| Brutowinst | €326.47m |
| Overige uitgaven | €183.65m |
| Inkomsten | €142.82m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
Aug 12, 2026
| Winst per aandeel (EPS) | 0.95 |
| Brutomarge | 32.94% |
| Nettowinstmarge | 14.41% |
| Schuld/Eigen Vermogen Verhouding | 23.7% |
Hoe presteerde 1SXP op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
1.1%
Huidig dividendrendement19%
UitbetalingsratioBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/22 08:52 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/09/30 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
SCHOTT Pharma AG & Co. KGaA wordt gevolgd door 23 analisten. 11 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Gaurav Jain | Barclays |
| Pallav Mittal | Barclays |
| Jonathon Unwin | Barclays |